Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Spectracef, Meiact
Cefditoren pivoxil is a third-generation cephalosporin antibiotic prodrug that is orally administered. It is converted to the active form, cefditoren, after absorption. Cefditoren inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to bacterial cell death. It is effective against a broad range of Gram-positive and Gram-negative bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and some strains of Staphylococcus aureus. Cefditoren is used to treat various bacterial infections, such as acute bacterial exacerbations of chronic bronchitis, pharyngitis/tonsillitis, uncomplicated skin and skin structure infections, and community-acquired pneumonia.
For treating bacterial infections such as acute bacterial exacerbations of chronic bronchitis, pharyngitis/tonsillitis, uncomplicated skin and skin structure infections, and community-acquired pneumonia.
Outcome:
Reduced cefditoren absorption
Mechanism:
Altered gastric pH
Outcome:
Increased risk of bleeding
Mechanism:
Cefditoren may interfere with vitamin K metabolism
Outcome:
Potential reduction in contraceptive efficacy
Mechanism:
Not fully established
Most likely new formulation: Extended-release formulation (Year: 2026, 70% confidence)
Based on historical data and current usage trends, cefditoren is expected to maintain its approved status for the foreseeable future with a 95% likelihood.
Cephalosporin, Antibiotic
Cephalosporin